IE51454B1 - High titer production of hepatitis a virus - Google Patents
High titer production of hepatitis a virusInfo
- Publication number
- IE51454B1 IE51454B1 IE1655/81A IE165581A IE51454B1 IE 51454 B1 IE51454 B1 IE 51454B1 IE 1655/81 A IE1655/81 A IE 1655/81A IE 165581 A IE165581 A IE 165581A IE 51454 B1 IE51454 B1 IE 51454B1
- Authority
- IE
- Ireland
- Prior art keywords
- hav
- virus
- growth stage
- cell culture
- purine
- Prior art date
Links
- 241000709721 Hepatovirus A Species 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000012510 hollow fiber Substances 0.000 claims abstract description 13
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001948 caffeine Drugs 0.000 claims description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 238000012606 in vitro cell culture Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 239000012528 membrane Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- QUNWUDVFRNGTCO-UHFFFAOYSA-N 1,7-dimethylxanthine Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282551 Cercopithecus Species 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32451—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/171,621 US4301249A (en) | 1980-07-23 | 1980-07-23 | High titer production of hepatitis A virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE811655L IE811655L (en) | 1982-01-23 |
| IE51454B1 true IE51454B1 (en) | 1986-12-24 |
Family
ID=22624494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1655/81A IE51454B1 (en) | 1980-07-23 | 1981-07-22 | High titer production of hepatitis a virus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4301249A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0044793B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5753410A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE20250T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1187413A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3174765D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK326781A (cg-RX-API-DMAC7.html) |
| ES (1) | ES504199A0 (cg-RX-API-DMAC7.html) |
| GR (1) | GR74594B (cg-RX-API-DMAC7.html) |
| IE (1) | IE51454B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT73371B (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783407A (en) * | 1985-09-30 | 1988-11-08 | Merck & Co., Inc. | Growth of hepatitus A virus in vero cells |
| DE3633550A1 (de) * | 1986-10-02 | 1988-04-14 | Behringwerke Ag | Vaccine gegen hepatitis a |
| US5268292A (en) * | 1988-06-27 | 1993-12-07 | Robertson Betty H | Reproducible generation of high yields of hepatitis A virus by cell culture |
| AU650711B2 (en) * | 1990-12-13 | 1994-06-30 | Cellco, Inc. | Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy |
| US5506129A (en) * | 1991-05-24 | 1996-04-09 | Evans Medical Limited | Virus production |
| DZ1706A1 (fr) * | 1992-08-07 | 2002-02-17 | Merck & Co Inc | Vaccin contre le virus de l'hepatite a. |
| US5354692A (en) * | 1992-09-08 | 1994-10-11 | Pacific Biotech, Inc. | Analyte detection device including a hydrophobic barrier for improved fluid flow |
| HRP950097A2 (en) * | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
| US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
| US20020182730A1 (en) * | 1995-07-26 | 2002-12-05 | Micheal L. Gruenberg | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| FR2821947B1 (fr) * | 2001-03-12 | 2003-05-16 | Canon Kk | Procede et dispositif de validation de parametres definissant une image |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| US20030134341A1 (en) * | 2001-09-19 | 2003-07-17 | Medcell Biologics, Llc. | Th1 cell adoptive immunotherapy |
| US20030175272A1 (en) * | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
| EP1497444B1 (en) * | 2002-03-27 | 2015-11-04 | Immunex Corporation | Methods for increasing polypeptide production |
| US20100028973A1 (en) * | 2006-09-26 | 2010-02-04 | Kyoto University | Method for proliferating hepatitis virus, hollow fiber for culturing hepatitis virus-infected cells, and use thereof |
| MX2009011899A (es) * | 2007-05-04 | 2010-03-30 | Baxter Int | Perfil de temperatura de dos pasos para la propagacion de virus. |
| JP5692688B2 (ja) * | 2008-06-26 | 2015-04-01 | 東洋紡株式会社 | 感染性ｃ型肝炎ウイルス粒子の製造方法、およびその利用 |
| WO2012122625A1 (en) | 2011-03-14 | 2012-09-20 | National Research Council Of Canada | Method of viral production in cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3615024A (en) * | 1968-08-26 | 1971-10-26 | Amicon Corp | High flow membrane |
| US3821087A (en) * | 1972-05-18 | 1974-06-28 | Dedrick R | Cell culture on semi-permeable tubular membranes |
| US3883393A (en) * | 1972-05-18 | 1975-05-13 | Us Health Education & Welfare | Cell culture on semi-permeable tubular membranes |
| US3997396A (en) * | 1973-07-02 | 1976-12-14 | Monsanto Company | Method for the in vitro propagation and maintenance of cells |
| US4087327A (en) * | 1976-04-12 | 1978-05-02 | Monsanto Company | Mammalion cell culture process |
| FR2398504A1 (fr) | 1977-07-29 | 1979-02-23 | Tours Inst Virologie | Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a |
| US4164566A (en) * | 1978-08-17 | 1979-08-14 | Merck & Co., Inc. | Hepatitis a virus cell culture in vitro |
| US4301250A (en) * | 1979-11-02 | 1981-11-17 | Merck & Co., Inc. | Method of producing hepatitis B surface antigen |
-
1980
- 1980-07-23 US US06/171,621 patent/US4301249A/en not_active Expired - Lifetime
-
1981
- 1981-07-14 CA CA000381716A patent/CA1187413A/en not_active Expired
- 1981-07-15 PT PT73371A patent/PT73371B/pt unknown
- 1981-07-20 GR GR65567A patent/GR74594B/el unknown
- 1981-07-22 DE DE8181401172T patent/DE3174765D1/de not_active Expired
- 1981-07-22 DK DK326781A patent/DK326781A/da not_active Application Discontinuation
- 1981-07-22 ES ES504199A patent/ES504199A0/es active Granted
- 1981-07-22 EP EP81401172A patent/EP0044793B1/en not_active Expired
- 1981-07-22 AT AT81401172T patent/ATE20250T1/de not_active IP Right Cessation
- 1981-07-22 IE IE1655/81A patent/IE51454B1/en not_active IP Right Cessation
- 1981-07-23 JP JP56114522A patent/JPS5753410A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5753410A (en) | 1982-03-30 |
| CA1187413A (en) | 1985-05-21 |
| DK326781A (da) | 1982-01-24 |
| GR74594B (cg-RX-API-DMAC7.html) | 1984-06-29 |
| EP0044793A2 (en) | 1982-01-27 |
| PT73371A (en) | 1981-08-01 |
| ES8205016A1 (es) | 1982-05-16 |
| PT73371B (en) | 1983-06-15 |
| US4301249A (en) | 1981-11-17 |
| IE811655L (en) | 1982-01-23 |
| DE3174765D1 (en) | 1986-07-10 |
| ATE20250T1 (de) | 1986-06-15 |
| EP0044793B1 (en) | 1986-06-04 |
| ES504199A0 (es) | 1982-05-16 |
| EP0044793A3 (en) | 1983-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4301249A (en) | High titer production of hepatitis A virus | |
| RU2314344C2 (ru) | Способ крупномасштабного производства вирусного антигена | |
| EP0056761B1 (en) | Method of producing hepatitis b surface antigen | |
| KR100968141B1 (ko) | 세포 배양물에서 바이러스의 증식 방법 | |
| CN103952376A (zh) | 培养细胞、增殖和纯化病毒的方法 | |
| Lieber et al. | S‐tropic murine type‐C viruses: Frequency of isolation from continuous cell lines, leukemia virus preparations and normal spleens | |
| WO1995024468A1 (en) | Hepatitis a virus culture process | |
| CN101979519A (zh) | 一种制备伪狂犬病疫苗的方法 | |
| JPH0748277A (ja) | Ａ型肝炎ウィルスワクチン | |
| CN103773741A (zh) | 笼式通气搅拌生物反应器制备流感疫苗的方法 | |
| CN1970080A (zh) | 用悬浮的Vero细胞生产病毒疫苗的方法 | |
| US4301250A (en) | Method of producing hepatitis B surface antigen | |
| CN100374552C (zh) | 大规模生产甲型肝炎病毒的方法 | |
| FI98377C (fi) | Adherentisti sitoutuneita soluja sisältävä matriisi ja menetelmä virus/virusantigeenin tuottamiseksi | |
| US5719051A (en) | Perfusion system and a method for the large scale production of virus or virus antigen | |
| Nicholson | Growth of fish cell lines on microcarriers | |
| Elliott | Nonperfused attachment systems for cell cultivation | |
| Manousos et al. | Feasibility studies of oncornavirus production in microcarrier cultures | |
| Johnson et al. | Production of Venezuelan equine encephalitis virus in cells grown on artificial capillaries | |
| SU1317021A1 (ru) | Штамм диплоидных клеток кожи и мышц эмбриона человека,используемый дл культивировани вирусов | |
| Thomson et al. | Growth of rubella virus in a glass bead propagator | |
| SU984214A1 (ru) | Лини перевиваемых клеток селезенки взрослой зеленой мартышки 455,используема дл культивировани вирусов | |
| RU2053297C1 (ru) | Способ культивирования вируса кори | |
| Looby et al. | The production of influenza virus by immobilised MDCK cells | |
| CN110257319A (zh) | 一种微载体上细胞维持培养的培养液及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK9A | Patent expired |